BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+19.43%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$4B
AUM Growth
+$4B
(+7.7%)
Cap. Flow
-$156M
Cap. Flow
% of AUM
-3.89%
Top 10 Holdings %
Top 10 Hldgs %
61.89%
Holding
76
New
7
Increased
10
Reduced
7
Closed
6
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$57.4M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$40.5M |
| 3 |
AC Immune
ACIU
|
$35.7M |
| 4 |
Annexon
ANNX
|
$31.8M |
| 5 |
89bio
ETNB
|
$24.6M |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$126M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$79.7M |
| 3 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$70.5M |
| 4 |
Aclaris Therapeutics
ACRS
|
$48.4M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$43.2M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.31B | 32.87% | 21,751,284 | – | – |
|
|
2
Revolution Medicines
RVMD
$7.1B
| $172M | 4.29% | 5,981,212 +2,000,000 | +50% | +$57.4M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $158M | 3.95% | 1,981,100 -150,000 | -7% | -$11.9M |
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $132M | 3.3% | 5,744,848 | – | – |
|
5
Kymera Therapeutics
KYMR
$2.95B
| $131M | 3.29% | 5,161,801 +422,797 | +9% | +$10.8M |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $129M | 3.23% | 4,370,024 | – | – |
|
7
Olema Pharmaceuticals
OLMA
$375M
| $128M | 3.21% | 9,135,893 | – | – |
|
|
8
Ionis Pharmaceuticals
IONS
$6.79B
| $123M | 3.07% | 2,428,613 -1,576,000 | -39% | -$79.7M |
|
9
Kura Oncology
KURA
$686M
| $106M | 2.65% | 7,373,228 +642,245 | +10% | +$9.24M |
|
10
4D Molecular Therapeutics
FDMT
$288M
| $81.2M | 2.03% | 4,007,413 | – | – |
|
11
Galapagos
GLPG
$2.07B
| $77.8M | 1.95% | 1,915,109 | – | – |
|
12
Merus
MRUS
$4.98B
| $75.7M | 1.89% | 2,752,420 | – | – |
|
13
Repare Therapeutics
RPTX
$71.7M
| $75.4M | 1.89% | 10,333,600 +2,041,612 | +25% | +$14.9M |
|
|
14
AC Immune
ACIU
$205M
| $72.9M | 1.82% | 14,571,236 +7,142,857 | +96% | +$35.7M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $69.8M | 1.75% | 8,774,570 -328,484 | -4% | -$2.61M |
|
16
Xoma
XOMA
$392M
| $67.2M | 1.68% | 3,633,743 | – | – |
|
|
17
IDEAYA Biosciences
IDYA
$2.15B
| $61.5M | 1.54% | 1,729,043 -3,554,446 | -67% | -$126M |
|
18
Zymeworks
ZYME
$1.12B
| $61M | 1.53% | 5,870,000 | – | – |
|
19
GH Research
GHRS
$837M
| $60.3M | 1.51% | 10,400,158 +1,125,000 | +12% | +$6.53M |
|
20
ESSA Pharma
EPIX
$11.4M
| $57.7M | 1.45% | 8,748,629 | – | – |
|
21
Janux Therapeutics
JANX
$1.37B
| $49.1M | 1.23% | 4,579,818 | – | – |
|
|
THRD
22
DELISTED
Third Harmonic Bio
THRD
| $47.9M | 1.2% | 4,365,933 | – | – |
|
|
23
89bio
ETNB
$1.34B
| $45.2M | 1.13% | 4,047,354 +2,201,200 | +119% | +$24.6M |
|
24
Relay Therapeutics
RLAY
$619M
| $43.7M | 1.09% | 3,970,045 +1,604,240 | +68% | +$17.7M |
|
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $41M | 1.03% | 890,072 -937,886 | -51% | -$43.2M |
|